Only a few days left before the shareholder meeting. Desperation is setting in for the manipulators. To cover or not to cover? That is the question. Let Vermillion Biotech (VRMLQ.pk) be a lesson to all those that doubt what happens when we marketing recaf. From .01 to 21.25. That's only 212,500% increase in share price. Why, because they have a cancer marker that got FDA approval and they were left for dead and those shorting got greedy (sounds very familiar) and now don't no what hit them. Shorts beware. It will be amusing to see a replay. You have been warned. Inverness may want to invest just as Quest did with Vermillion. Never say never.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.